Pure red cell aplasia after treatment of renal anaemia with epoetin theta

Clinical Kidney Journal

Volumn 6, Issue 5, 2013, Pages 539-542

  Wieser, Clemens ^a   Rosenkranz, Alexander R ^b  

^a Klinikum Klagenfurt   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

anti erythropoietin antibodies; biopharmaceuticals; pure red cell aplasia

Indexed keywords

CREATININE; CYCLOSPORIN A; ERYTHROPOIETIN ANTIBODY; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISOLONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

AGED; ANTIBODY TITER; ARTICLE; BACTEROIDES; BIOASSAY; CASE REPORT; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE INCREASE; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; GLOMERULONEPHRITIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; IRON BLOOD LEVEL; KIDNEY DISEASE; KIDNEY FAILURE; MALE; PERITONITIS; PREVOTELLA MELANINOGENICA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RENAL ANEMIA; RENAL REPLACEMENT THERAPY; RETICULOCYTE COUNT; TRANSFERRIN BLOOD LEVEL; TREATMENT FAILURE;

EID: 84885044293     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sft085     Document Type: Article

References (17)

1. McKoy JM, Stonecash RE, Cournoyer D et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008; 48: 1754-1762
2. Macdougall IC, Roger SD, de Francisco A et al. Antibodymediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis- stimulating agents: new insights. Kidney Int 2012; 81: 727-732
3. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475
4. Covic A, Cannata-Andia J, Cancarini G et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know-a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 2008; 23: 3731-3737
5. Dorner T, Strand V, Castaneda-Hernandez G et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheumat Dis 2013; 72: 322-328
6. KDIGO. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012; (Suppl 2): 279-335
7. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol. 2008; 36: 1573-1584
8. Aranesp Summary of Product Characteristics. 2012. http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/000332/ WC500026149.pdf (22 May 2013, date last accessed)
9. Mircera Summary of Product Characteristics. 2012. http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/000739/ WC500033672.pdf (22 May 2013, date last accessed)
10. Eprex Summary of Product Characteristics. 2012. http://www. medicines.org.uk/emc/medicine/889/SPC/Eprex+2000%2c +4000+and+10000+IU+ml+solution+for+injection+in+prefilled+ syringe (22 May 2013, date last accessed)
11. NeoRecormon Summary of Product Characteristics. 2012. http://www.medicines.org.uk/emc/medicine/7747/SPC/Neorecormon +Solution+for+Injection+in+Pre-Filled+Syringe (22 May 2013, date last accessed)
12. Arakawa T, Philo JS, Ejima D et al. Aggregation analysis of therapeutic proteins: part 1. Bio Process Int 2006; 4: 32-42
13. Locatelli F, Aljama P, Barany P et al. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? Nephrol Dial Transplant 2004; 19: 288-293
14. Kromminga A, Schellekens H. Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann N Y Acad Sci 2005; 1050: 257-265
15. Thorpe R, Swanson SJ. Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin Diagn Lab Immunol. 2005; 12: 28-39
16. Casadevall N. Immune-Response and Adverse Reactions: PRCA Case Example. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/Presentation/2009/11/ WC500011064.pdf (22 May 2013, date last accessed)
17. Cournoyer D, Toffelmire EB, Wells GA et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004; 15: 2728-2734